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Abstract: 
Understanding the mechanisms of migraine remains challenging as migraine is not a 
static disorder, and even in its episodic form migraine remains an “evolutive” chronic 
condition. Considerable progress has been made in elucidating the pathophysiological 
mechanisms of migraine, associated genetic factors that may influence susceptibility 
to the disease, and functional and anatomical changes during the progression of a 
migraine attack or the transformation of episodic to chronic migraine. Migraine is a life 
span neurological disorder that follows an evolutive age-dependent change in its 
prevalence and even clinical presentations. As a disorder, migraine involves recurrent 
intense head pain and associated unpleasant symptoms. Migraine attacks evolve over 
different phases with specific neural mechanisms and symptoms being involved during 
each phase.  In some patients, migraine can be transformed into a chronic form with 
daily or almost daily headaches. The mechanisms behind this evolutive process 
remain unknown, but genetic and epigenetic factors, inflammatory processes and 
central sensitization may play an important role.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Migraine is a recurrent, disabling neurological disorder, involving intense head pain 
and associated with other unpleasant symptoms. Migraine affects about 15% of the 
general population (1) and causes substantial personal suffering and impaired quality 
of life with a significant socioeconomic impact. The toll of chronic migraine on 
individual and society is even bigger, as up to 45% of patients presenting to headache 
clinics have daily or near-daily headaches (2, 3), with nearly half of them in need of a 
migraine preventive treatment (4).  The World Health Organization ranks migraine as 
the most prevalent, disabling,  long-term neurological condition when taking into 
account years lost due to disability (5).  
Considerable progress has been made in elucidating the pathophysiological 
mechanisms of migraine, associated genetic factors that may influence susceptibility 
to the disease and functional and anatomical changes during the progression of a 
migraine attack, or the transformation of episodic to chronic migraine. However, 
understanding disease mechanisms remains challenging as migraine is not a static 
disorder, and even in its episodic form migraine remains an “evolutive” chronic 
condition. 
 
Migraine as a life span disorder 
Migraine is a life span disorder affecting children, adults and the elderly. The clinical 
presentation of migraine shows an age-dependent change with shorter duration and 
also occurrence of special paroxysmal symptoms like vomiting, abdominal pain or 
vertigo in childhood and largely an absence of autonomic signs in the elderly.   
The prevalence of migraine in children varies, depending on the study and the age 
range of the included subjects, between 2.7% and 10.0% and in younger children 
(below 7 years) it does not differ between girls and boys (6, 7). In adulthood, migraine 
is more prevalent in women than in men with a lifetime prevalence of 12-17% and 4-
6%, respectively (8, 9). A factor that may contribute to the increased prevalence of 
migraine in women compared to men in the reproductive years is estrogen withdrawal 
which is a reliable trigger of menstrual attacks in women (10). Migraine in women 
usually declines after menopause (11, 12), indicating further the influence of hormonal 
changes on migraine occurrence. The prevalence of migraine in the elderly is about 
3.5% with females affected ~2 times more often than males (13, 14).   
The clinical manifestation of migraine is different in childhood from that in adulthood. 
Pediatric migraine is characterized by shorter attacks with the pain being less often 
unilateral. Accompanying symptoms include mild intolerance to light and rarely to 
noise (15), while vomiting and cranial autonomic features are  significantly more 
frequent compared to adult patients (16, 17).  
Beyond the influence of hormonal changes in women that can be partially responsible 
for the changes in the prevalence of migraine in adults and the elderly, another general 
feature seems to be a decrease in autonomic symptoms during aging.  All these 
symptoms are associated with increased parasympathetic activity. A possible 
explanation is a change in the connectivity of hypothalamic areas to different 
autonomic control centres during aging in migraine (18). Readers interested in 
changes in migraine symptoms during lifespan, as well as, in mechanisms that may 
be driving these changes, are encouraged to read a recent review by Straube and 
Andreou (18). 
  
Genetic and epigenetic component of migraine 
Genetic factors may determine susceptibility to migraine, while different environmental 
factors can contribute to the development of a migraine attack (19, 20). Mainly through 
genome-wide association studies (GWAS), which tested for differences in allele 
frequencies of single nucleotide polymorphisms (SNPs) over the genome in migraine 
patients and controls (21), it is now understood that multigenetic variants, rather than 
individual genes, influence the susceptibility to migraine. Although GWAS in migraine, 
similarly to other disorders studied with GWAS (22), failed to shed light on the 
molecular changes that are responsible for the evolutive nature of migraine, one can 
envisage that combined knowledge from many variants will highlight which molecular 
pathways potentially could be involved in migraine pathophysiology (20).  
In the latest GWAS which included samples from nearly 60, 000 patients and over 
300,000 controls, 44 SNPs were associated with migraine without aura, implicating 38 
distinct genomic loci (23). The majority of them were found to be implicated in 
molecular pathways related to vascular function. Other loci identified in this study, 
were involved in pathways related to metal ion homeostasis, leading to a rather 
unexpected, hypothesis that metal ion homeostasis might contribute to migraine 
susceptibility. Only a handful of loci was found to be involved in ion channel activity, 
with much less prominent signals (20). The importance of those compared to the 
outcomes related to vascular function, remains a matter of debate, as this study 
highlighted that vascular dysfunction is of great importance in migraine susceptibility 
with neuronal dysfunction playing a rather secondary role (20).  
Regardless of these outcomes, due to their small effect size no single SNP has any 
clinical use in predicting the risk of developing migraine.  There is still a big challenge 
in the field of GWAS to link associated SNPs to actual genes and pathways. GWAS in 
migraine are yet to offer further knowledge on the functional consequences of the 
associated SNPs and how they influence susceptibility to migraine. 
On the other hand,  genetic studies of hemiplegic migraine, a rare monogenic forms 
of migraine (24) offered knowledge about specific genes that encode proteins involved 
in the function of ion channels and transporters. Specific mutations in these genes 
were studied in detailed and were shown to induce either loss or gain of function in 
cellular assays or in mutant murine. In brief, mutations involved in familial hemiplegic 
migraine were found in the genes CACNA1A, ATP1A2 and SCN1A, which encode 
subunits of neuronal voltage-gated CaV2.1 Ca2+, NaV1.1 Na+ channels, and glial 
Na+K+ ATPases, respectively. Interestingly a common consequence of these 
mutations is an increase in glutamate availability at the synaptic cleft of cells. 
Mutations in the CACNA1A gene can have as a consequence enhanced glutamate 
release due to enhanced calcium flux at the presynaptic terminal (25). Mutations in the 
ATP1A2 gene result in a smaller electrochemical gradient for Na+. One effect of this 
is the reduction or inactivation of astrocytic glutamate transporters, leading to a build-
up of synaptic glutamate (26). The SCN1A mutations can result in facilitation of high-
frequency discharges that might also increase synaptic glutamate levels (27). Thus, 
the neurons at glutamatergic synapses can fire at a higher frequency than they do 
under normal conditions and this might explain the increased susceptibility to cortical 
spreading depression, the underlying mechanism of migraine aura (28, 29). 
Interestingly, mice carrying the CACNA1A mutation exhibit blunted trigeminovascular 
nociceptive responses and calcitonin gene-related peptide (CGRP) expression (30, 
31).  
Although genetic factors may be involved in the evolutive processes of migraine, to 
date they failed to explain the pathophysiology of migraine and evolutive mechanisms. 
However, it is important to mention the knowledge gained from such studies, as they 
are part of disease mechanisms and disease susceptibility, while in the future they 
may be able to explain better the mechanisms that transform migraine into a chronic 
form in some individuals or achieve migraine freedom altogether later in life. 
 
Is there a role for epigenetic mechanisms in migraine susceptibility and 
chronification? 
Beyond genetic factors that could be responsible for migraine susceptibility and 
evolution to migraine chronification, epigenetic pathways through changes in DNA 
expression could also influence an individual’s sensitivity to migraine. Epigenetics 
refers to modification of gene expression without altering the underlying DNA 
sequence. A main epigenetic mechanism is DNA methylation, the covalent addition 
of a methyl group to the fifth carbon of cytosine residues, which is typically associated 
with gene silencing. The cause of epigenetic changes in not well understood, but it 
can include environmental factors, early life events, inflammation, stress and brain 
plasticity.  
Epigenetics is a new area of research and only a handful of studies are done in 
migraine patients. Recently, the first genome-wide study of DNA methylation in 
headache chronification was published (32). Although, several potentially implicated 
loci and processes were identified, only in the combined meta-analysis statistical 
significance was found for two CpG sites which were related to two brain-expressed 
genes; SH2D5 and NPTX2. The H2D5 gene encodes the SH2 domain-containing 5 
protein which is thought to regulate indirectly synaptic plasticity through the control 
of Rac-GTP levels. The NPTX2 gene encodes the neuronal pentraxin II protein, an 
inhibitor of excitatory synapses, through binding and clustering of glutamatergic 
AMPA receptors. Both proteins are highly expressed in the adult human brain (32).  
A smaller pilot study aimed to identify changes in DNA methylation associated with 
headache chronification by characterising genome-wide DNA methylation levels in 
episodic migraineurs and patients suffering from chronic migraine with medication 
overuse headache (MOH), before and after detox programme. Although no statistical 
significance was found between the groups at different time points, some CpG sites 
of interest were identified, and are thought to be involved in drug addiction 
mechanisms and neuropsychiatric illness comorbid (33).  
These preliminary data seem to support a role of epigenetic processes migraine, and 
theoretically they could be involved in mechanisms of brain plasticity and other 
migraine-specific processes. However, considering that migraine, both in its episodic 
and chronic form, is a complex and multidimensional disorder, all these preliminary 
data require replication and validation in much larger samples. 
 
Brain changes in the migraineur: Is it a brain evolutive process? 
Beyond functional changes, differences in the structural brain integrity, involving both 
the white and gray matter, which evolve over time, have been reported by several 
studies between migraine patients and controls.  
The prevalence and volume of deep white matter lesions is increased in migraine 
patients, with women with migraine with aura having the highest prevalence (34-36). 
Interestingly, these white matter lesions are not static and their development involves 
a gradual process for the evolution of focal invisible microstructural changes into 
focal migraine-related visible white matter lesions (37). Later studies showed long-
term higher incidence of deep white matter brain changes, especially among female 
patients. These changes were related to an increased number of new lesions rather 
than an increase in the size of pre-existing lesions (38). In the ARIC MRI study (39), 
the authors showed that although migraine has an increased insistence of white matter 
lesions, there is no progression overtime. The authors suggest that the association 
between migraine and white matter lesions is stable in older age and may be 
attributable to changes occurring earlier in life (39). Indeed, although white matter 
lesions are not as prevalent in children, they are not unusual (40-42). Whether these 
early life changes are attributed to genetic factors, remains to be established, however, 
the outcomes of the GWAS on vascular factors that may contribute to migraine 
susceptibility, may also suggest an increased susceptibility to white matter lesions.  
A number of studies showed cortical structural changes in migraine patients (detail 
reviews can be found here (43-47). To this end there are conflicting results to whether 
there is cortical thinning or cortical thickening in the migraineur´s brain. Such changes 
include, increased thickening in the somatosensory cortex of patients with migraine 
that does not differ between patients with and without aura, decreased grey matter in 
cingulate cortex and reduced volume of the medial prefrontal cortex, atypical age-
related cortical thinning in episodic migraine, increased thickness of the left middle 
frontal sulcus and the left temporo-occipital incisure, as well as, reduced thickness of 
the left superior frontal sulcus and the left precentral sulcus (48-52). A more recent 
multi-centre 3T MRI study utilising a large number of migraine patients (131) 
demonstrated significant clusters of thinner cortex in the patients with migraine 
compared with control subjects (53).  
Gray matter changes have been reported in the region of the thalamus and a reduced 
striatal volume in migraine subjects with and without aura. Studies have shown broad 
microstructural alterations in the thalamus of migraine patients that may underlie 
abnormal cortical excitability. These changes involve reduced volume in thalamic 
nuclei with dense connections to the limbic system, including the central nuclear 
complex, anterior nucleus and lateral dorsal nucleus (54, 55). Migraineurs were also 
found to have structural alterations of the brainstem with significant inward 
deformations in the ventral midbrain and pons, and outward deformations in the lateral 
medulla and dorsolateral pons (56).  
An interesting study by Coppola and colleagues demonstrated that structural changes 
in the brain of episodic migraine patients without aura evolve over the course of 
the migraine cycle. Interictally, patients were shown to have a significantly lower gray 
matter density within the right inferior parietal lobule, right temporal inferior gyrus, right 
superior temporal gyrus, and left temporal pole when compared to healthy controls. 
Ictally, gray matter density increased within the left temporal pole, bilateral insula, and 
right lenticular nuclei, but no areas exhibited decreased density. The authors 
suggested that these morphometric changes between ictal and interictal phases 
indicate abnormal structural plasticity (57). Whether these changes are an important 
mechanism of migraine pathology remains to be evaluated. If indeed these data can 
be reproduced, they demonstrate that evolutive processes happen in the migraineur´s 
brain constantly and in a cycling manner. 
In CM patients, white-matter abnormalities were found in the brainstem and 
cerebellum (58). Other studies showed, that CM is associated with subtle gray matter 
volume changes in several brain areas known to be involved in nociception/anti-
nociception, multisensory integration, and analgesic dependence (59, 60). Gray 
matter changes, have been reported to correlate with headache frequency assessed 
in both episodic and chronic migraine (59). Recently, another study demonstrated 
alterations in the region of the hypothalamus, with the volume of the hypothalamus 
being significantly decreased in both episodic and chronic migraine patients, which in 
CM was positively correlated with headache frequency (61). Bigger 
longitudinal volumetric neuroimaging studies with larger groups, especially on the 
chronification of migraine, are needed to understand the evolutive nature of these 
changes. 
What causes these structural changes in the migraine brain is not known. Some 
alterations may be due to a genetic susceptibility towards developing migraine attacks. 
To this end, structural brain studies in paediatric migraine patients, could shed more 
light in the cause of this structural changes. A small MRI study showed significant 
alterations in brain volume. Compared to controls, paediatric migraine patients 
experienced a significant gray matter loss in several areas of the frontal and temporal 
lobes which are part of the pain-processing network, while they had increased gray 
matter volume of the right putamen. Between patients with aura compared to patients 
without aura, the left fusiform gyrus had an increased volume. In the paediatric 
population of migraine these structural changes were not correlated with disease 
duration and attack frequency (62). A more recent study that used MRI apparent 
diffusion coefficient (ADC) found no volumetric changes in paediatric migraine 
patients, but demonstrated increased ADC in the region of the hippocampus, 
brain stem and the thalamus (63). Although these studies used a smaller number of 
patients, data suggest that brain abnormalities do occur early on in migraine patients 
and the absence of correlation with patient clinical characteristics suggest that they 
may represent a phenotype developed as a consequence of genetic susceptibility. 
Other changes could be a consequence of repeated head pain attacks. Such structural 
changes can be the result of brain plasticity, which is defined as the ability of the brain 
to modify its own structure and function following changes within the body or in the 
external environment. A number of CNS changes can contribute towards gray matter 
changes, such as synaptogenesis, angiogenesis, glia genesis, neurogenesis, 
increase in cell size, increase in myelin size and increase in blood flow or interstitial 
fluid. White matter changes are usually the result of axonal remodelling and changes 
in blood flow (64). Despite the number of reports of structural changes in the 
migraineur´s brain, their importance in the biology of migraine remains uncertain. 
Nevertheless, the existence of structural changes, suggest that migraine induces 
progressive anatomical transformation in the brain that may have an evolutive role in 
disease progression and associated disability.  
 
The evolutive migraine attack 
Migraine is cyclic disorders with a complex sequence of symptoms within every 
headache attack. In its episodic form, migraine is characterised by recurrent attacks 
involving different phases: (a). A premonitory phase prior to the onset of the actual 
headache, characterised by symptoms, such as excessive yawning, thirst, 
somnolence, food craving, cognitive difficulties, and mood changes (65) (b). Transient 
neurological symptoms, known as migraine aura (typically visual alterations), that 
occur just before the actual headache starts (66).  (c). An intense headache attack, 
usually involving only one site of the head, which can be exacerbated by movement 
and accompanied with hypersensitivity to sensory stimuli (e.g. light and smells), 
nausea (67). (d) The postdrome phase which is mainly characterised by symptoms of 
fatigue, difficulties in concentration and comprehension, and neck stiffness (68). 
During the interictal phase, although patients may appear normal, genetic 
predisposition and a number of triggers make them susceptible to an attack. 
Several factors may trigger migraine; stress and lack of sleep are probably the most 
common (69). Significant advances have been made in characterising migraine as a 
brain disorder and in identifying evolutive functional changes in different brain areas 
during the different phases of a migraine attack (Figure 1).  However, despite the 
number of studies on pain pathways involved during the headache phase (70), the 
molecular changes that actually trigger a migraine attack in the brain remain unknown. 
The lack of such knowledge had significantly hampered the design of migraine-specific 
and effective preventive treatments for a long time. Emerging evidence, partly 
obtained through use of the newly designed migraine treatments designed against the 
calcitonin gene-related peptide (CGRP) and its receptors (71), further highlights an 
important role of the trigeminal system in driving migraine attacks.  
 
The premonitory phase and the triggering mechanisms of migraine  
 
Accumulating evidence exists as to why the trigger of migraine attacks should be 
sought in the hypothalamus. The hypothalamus is a small brain structure, consisted 
by a number of different nuclei with distinct neuropharmacology and function. Its 
multitude of functions can, in a broader sense, be described as functions that organise 
the circadian rhythms, control and maintain the homeostasis and regulate arousal (72).  
Migraine onset appears to have a circadian rhythmicity. Migraine attacks tend to occur 
in a daily, monthly or even seasonal pattern, further suggesting a role for hypothalamic 
areas, responsible for the entrained biological clock-function, in the development of 
the disease (73, 74). Morphological and functional gender differences in several nuclei 
of the hypothalamus, may be also responsible for the monthly, menstrual associated 
migraine attacks, and the increased prevalence of migraine in women (~3:1) (75). 
The premonitory symptoms of migraine are strongly associated with homeostatic 
functions regulated by the hypothalamus, such as arousal, sleep and feeding. The 
strongest, direct evidence for hypothalamic activation in migraine patients arises from 
brain imaging studies. These studies demonstrated, using positron emission 
tomography, increased blood flow in the region of the hypothalamus during the very 
early stages of spontaneous migraine attacks (76, 77) and during the premonitory 
phase of nitroglycerin (nitric oxide-NO donor)-induced migraine attacks (78).  
A disturbance in homeostatic function is a significant trigger of attacks (69). 
Sleep/arousal physiology in particular, deserves greater attention as sleep 
disturbances can trigger attacks in over 50% of migraine sufferers. Additionally, 
patients with both episodic and chronic migraine are more prone to have their attacks 
in the morning (79). Morning headaches are also common in patients with sleep 
disorders, while post-operative migraine attacks in patients are common following 
anaesthesia (80). Importantly, sleep itself has a striking effect as an abortive strategy 
(81), particularly for the majority of patients who find no relief by pharmacological 
treatments. The discovery of a mutation in the clock-gene CK1δ, causing so called 
familiar advanced sleep phase syndrome, was strongly linked to migraine both 
clinically and experimentally in mice engineered to carry this mutation (82). The 
increased comorbidity of migraine in narcolepsy (83) and sleepwalking (84), also 
supports that migraine is an arousal-related disorder.  
Such evidence highlights that the posterior region of the hypothalamus containing the 
circuitry for governing arousal and the transition between sleep and wake, has a key 
role in the triggering of migraine. However, which hypothalamic nuclei, 
neurotransmitters and through which mechanisms, may be implicated has not been 
investigated. Although several neurochemical pathways may be involved in migraine 
pathophysiology (85), of them, dopaminergic mechanisms  appear to play some role, 
as yawning, a dopaminergic-driven function, is a prevalent symptom during the 
premonitory phase of migraine. In animal models the dopaminergic A11 nucleus of the 
hypothalamus has been shown to project to the trigeminocervical complex (86), an 
important relay system involved in migraine, and to modulate activation of the 
ascending trigeminothalamic pathway (87, 88). Additionally, the A11 nucleus has been 
shown to be susceptible to nitric oxide donors in animal models of migraine (89, 90). 
 
Of interest, an fMRI study of daily brain scans in a migraine patient reported a strong 
association for both hypothalamic and cortical activity during the premonitory phase of 
an attack(77). The involvement of the occipital cortex in migraine has been long 
recognised, in particular because of the visual aura phenomenon.   
Electrophysiological studies and studies using transcranial magnetic stimulation, 
suggest that migraineurs have altered cortical activity, withi the cortex, particularly the 
occipital region, appearing hyperactive (91, 92). A study of photophobia during 
spontaneous migraine attacks using PET imaging also found that this migraine 
symptom is linked with visual cortex hyperexcitability (93, 94). It has been suggested 
that thalamo-cortical dysrhythmia in migraine patients may be responsible for 
abnormal cortical responses (95). Hence, a focal cortical treatment for migraine 
without systemic side effects is an attractive treatment opportunity. To this end, single 
pulse TMS (sTMS) has been shown to supress activation of the ascending trigemino-
thalamic pathway (96) and is now an approved migraine treatment with good efficacy 
in the acute and preventive treatment of migraine (97-99).  
 
The migraine aura 
 
Migraine with aura symptoms are typically seen in about 15-20% of patients (100) and 
usually they develop gradually over 15-20 minutes and last less than 60 minutes (67). 
It is now believed that the aura is the result of so called cortical spreading depression 
(CSD) (101). fMRI studies that tried to capture or simulate aura in migraine patients 
also pointed to a role for CSD as a mechanism for migraine aura (102, 103). CSD is a 
wave of cortical neuronal depolarisation, linked with depressed neuronal activity and 
blood flow changes (104), which in migraine is believed to spread out from the occipital 
cortex. In animals, CSD is an NMDA-receptor depended process and can be induced 
by cortical stimulation (105). It remains enigmatic how CSD is triggered in patients 
during migraine aura. Potentially, if indeed cortex is hyperactive in patients, this 
hyperactivity could trigger a CSD in certain susceptible patients. As previously 
mentioned genetic predispositions and environmental factors may modulate individual 
susceptibility by lowering the CSD threshold and cortical excitation may cause 
sufficient elevation in extracellular K+ and glutamate to initiate CSD (26). Of interest, 
blood flow changes suggest a functional role for the cortex and this has also been 
recorded in migraine patients without aura (101).  
 
The discussion of CSD-induced headache in migraine is still a matter of debate, as 
not every migraine patient experiences migraine aura, while the occurrence of aura 
without a headache is not uncommon (106). In experimental animal modes, CSD was 
shown to induce edema, reflex middle meningeal vasodilation and increases neural 
activity in the ipsilateral trigeminal ganglion and trigeminal nucleus (107-110). It was 
demonstrated that the trigeminal activation produced by experimental CSD may cause 
inflammation in the meninges that occurs after the CSD has subsided (111). 
Contradicting preclinical data to these previous findings also exists (112, 113). An 
alternative hypothesis suggests that CSD activates cortico-thalamic fibres that in turn 
sensitize it is the activation of third order neurons of the ascending trigemino-thalamic 
pathway by cortico-thalamic fibres that become activated during a CSD (114).  
 
 
The headache phase 
 
The headache phase of migraine involves activation of the ascending 
trigeminothalamic pathway. Through early observations in humans who underwent 
awake brain surgery, it became well established that the pain during a migraine attack 
is perceived to be felt on intracranial structures, such as, the dura matter and 
intracranial vasculature (115). The sensory innervation of these structures arises from 
the trigeminal nerve, mainly from unmyelinated C-, and thinly myelinated Aδ-fibres, 
which have their cell bodies in the trigeminal ganglion. Nociceptive activation of the 
trigeminal fibres is referred to as “trigeminovascular activation”. The trigeminal fibres 
that transmit sensory information from such intracranial structures synapse on second-
order neurons within the trigeminocervical complex (TCC; trigeminal nucleus caudalis, 
C1 and C2 spinal levels). These neurons give rise to the main ascending trigemino-
thalamic pathway that relays sensory information to third order neurons, mainly in the 
contralateral thalamus, before processing the information to higher cortical areas.  
The thalamus is a pivotal nucleus for multisensory integration and may be a strong 
candidate for influencing neuronal excitability in migraine. The thalamic area is a 
prominent site of action of triptans (116), of clinically active preventives (117, 118) and 
of other potential anti-migraine compounds (119). Neuroimaging and 
electrophysiological studies have revealed altered network connectivity between the 
thalamus and pain modulating/pain encoding cortical areas during spontaneous 
migraine attacks, as well as, thalamo-cortical dysrhythmia which correlate with 
migraine symptoms (120, 121). Recently, a dynamic functional connectivity study in 
migraine patients between attacks demonstrated abnormal thalamo-cortical network 
dynamics, with the medial and posterior thalamic nuclei identified in intrinsic 
subcortical connectivity networks (122). The role of the thalamus in migraine deserves 
higher attention given its involvement in the development of associated symptoms, 
such as hypersensitivity to visual stimuli (123), while thalamo-cortical activation may 
also participate in the development of auditory sensitivity (124). Furthermore, 
sensitization of third order thalamic neurons has been implicated in the development 
of non-cranial allodynia that is frequently seen in migraine patients (125).  
 
A complex of descending networks from multiple brainstem, midbrain and cortical 
nuclei modulate the excitability of the ascending trigemino-thalamic pathway (126). In 
the absence of any evidence of malfunction in the peripheral trigeminovascular 
system, a disruption of normal endogenous descending modulatory tone may play a 
critical role in migraine. To this end, a number of brain imaging studies showed 
increased blood flow in the region of the dorsal rostral pontine and brainstem in both 
episodic (127, 128) and chronic migraine patients (129). A great limitation of brain 
imaging to date, is the lack of spatial resolution. Hence, it remains a lot of future 
research to delineate which descending networks and neurotransmitters that 
potentially are involved. Candidate nuclei include the periaqueductal gray, locus 
coeruleus, dorsal raphe nucleus and nucleus raphe magnus. Initially, these loci were 
considered as the migraine generator, due to the persistent blood flow increased in 
the rostral pontine area following headache relief (130). However, the increased blood 
flow in this region may be expected given the role of the brainstem in descending 
modulatory control of pain. What is interesting is that functional connectivity fMRI 
studies between attacks, have identified numerous brain regions and functional 
networks with atypical functional connectivity in migraineurs, and demonstrated 
interictal impairment of the descending pain modulatory circuits, potentially indicating 
a reduction of pain inhibition in migraineurs (131).   
The puzzle of migraine pathophysiology is still incomplete, as we are yet to understand 
how hypothalamic dysfunction may lead to activation of the ascending 
trigeminothalamic pathway (Figure 2). Activation of indirect pathways, involving 
brainstem nuclei as discussed above may indeed be a possibility. Alternatively, 
pathways arising from the hypothalamus that project directly to the TCC or the sensory 
thalamus, such as the dopaminergic A11 nucleus or the histaminergic 
tuberomammillary nucleus, both located in the posterior region of the hypothalamus, 
may directly alter the function of the ascending trigeminothalamic pathway.  
An equally important pathway may be the trigeminal autonomic activation in migraine 
driven by the hypothalamus. Although autonomic features in migraine are not as 
prominent as in trigeminal autonomic cephalalgias, increased parasympathetic activity 
signs can be frequent (132). Clinical evidence suggest that subjects with 
cranial autonomic symptoms have a hyperactive efferent arm 
of trigeminal autonomic reflex (132).  The hypothalamus is regulating the autonomic 
system and may indeed drive indirectly activation of the trigeminal system through the 
trigeminal-autonomic arc. The vast majority of parasympathetic fibers innervating the 
cerebral blood vessels originate from the sphenopalatine and the otic ganglia (133). 
Sphenopalatine ganglion block in migraine patients with autonomic features was found 
to relieve the pain intensity by over 50% (134). These findings suggest that increased 
parasympathetic tone contributes to the activation of perivascular nociceptors 
contributing significantly to the pain intensity and possibly to the initiation of central 
sensitization (135). This could also explain a brain-driven activation of the peripheral 
trigeminal system and the release of CGRP from trigeminal fibers and cells located in 
the trigeminal ganglion. The increased cranial parasympathetic outflow and 
modulation of the trigeminal autonomic reflex by the hypothalamus in migraine may 
be of great importance. 
 
The trigeminal system and its role in sustaining the head pain in migraine 
Despite the various evidence of increased blood flow changes in different brain nuclei 
before or during the onset of the headache phase, what really alters the excitability of 
the ascending trigemino-thalamic pathway in a manner that a migraine headache may 
develop in susceptible individuals remains to be revealed. Several lines of evidence 
suggest that the peripheral trigeminal system is of pivotal importance in driving the 
headache; 
a. The referred pain patterns of migraine headache are similar to the locations of 
referred pain after stimulation of meningeal and cerebral arteries, as observed 
in awake patients during brain surgery (115, 136-138). The importance of these 
pain-sensing structures is their vast innervation by trigeminal fibres.  
b. CGRP levels are increased during migraine attacks. Blood samples from 
patients or animal models during stimulation of the trigeminal fibres suggest 
that the origin of the CGRP found in migraine patients is indeed from the 
trigeminal nerve (139-141). CGRP is a potent vasodilator in the periphery and 
a modulator of nociceptive activity centrally. On second order neurons, CGRP 
has no effect on spontaneous neuronal firing but it can facilitate glutamatergic 
activity and nociceptive activation (142-144).  
c. Chemicals that do not cross, the otherwise intact, blood-brain barrier (BBB) in 
sufferers (145-147), such as CGRP and histamine, can trigger a migraine attack 
(148, 149). It is worth pointing out that the origin of the pain is not vasodilation 
as originally thought, as the migraine headache is not associated with cerebral 
or meningeal vasodilation (150), and hence anti-migraine treatments may not 
require vasoconstrictor properties. Additionally, healthy controls are not 
susceptible (or respond to a much lower degree) to migraine headache 
following provocation with such chemicals, suggesting that the trigeminal 
system in migraine patients is sensitized.  
c. d. Effective migraine treatments, like the hydrophilic sumatriptan, the large 
monoclonal antibodies against the CGRP system and the peripherally injected 
botulinum toxin (151-153), do not cross the BBB. Hence, any direct or indirect 
mechanism of action involves the peripheral trigeminal fibres and the trigeminal 
ganglion that are outside the BBB (154).  
 
 
The above evidence, do not suggest that the peripheral arm of the trigeminal system 
is the cause of migraine, but demonstrate an important role for the peripheral 
trigeminal system in migraine headache. This evidence further suggests that 
treatments that can block activation of this system could be effective in suppressing 
migraine, but not necessarily the generator of migraine attacks. The trigeminal system, 
as well as, the trigemino-thalamic pathway in the CNS, are excitatory pathways, with 
glutamate being the major excitatory neurotransmitter (155). An ideal treatment for 
migraine would block the glutamatergic transmission along these pathways, as this 
will inhibit painful signals reaching pain processing cortical centres. However, central 
glutamatergic blockade is challenging due to severe adverse events that can develop 
by inhibiting glutamatergic transmission, although not impossible (71, 117). 
Peripherally acting glutamate agonists and antagonists may offer a more promising 
treatment approach (156, 157).  
 
Vascular changes in migraine 
Vascular changes in migraine were for a long time considered the driver of migraine 
pain. In 1940 Ray and Wolff reported that stimulation or distension of the large cranial 
arteries evoked head pain associated with nausea (115). Distention of the distal 
internal carotid artery and middle cerebral artery during balloon inflation in patients 
with intracerebral arteriovenous malformations, can induce focal headache (158). 
Several studies attempted to analyse the role of the dural vasodilation by measuring 
blood vessel diameter during an attack. A 3T magnetic resonance angiography (MRA) 
study during a spontaneous migraine attack showed no significant changes of the 
diameter of middle meningeal artery (MMA) during a spontaneous migraine attack 
(159), however a larger study in cilostazol-induced migraine attacks, found that the 
onset of migraine is associated with increase in MMA circumference specific to the 
headache side (160). In different studies in migraine patients with unilateral headache, 
headache was associated with intracranial dilatation of the middle cerebral artery 
(MCA) on the painful side, which was normalised after treatment with sumatriptan 
(161), as well as, with dilatation of the temporal artery (162).Spontaneous dilatation 
alone cannot explain migraine pain, as arteries may dilate markedly, such as during 
blood pressure decreases, without induction of a migraine attack. In a nitroglycerin-
triggered migraine study, peak dilation of the MCA occurred during the infusion phase 
of nitroglycerin. However, a migraine attack fulfilling the International Headache 
Society diagnostic criteria occurred ~5h post infusion, suggesting a role of the cGMP 
pathway in the development of a migraine attack, rather than the vasodilation itself. 
These evidences suggest that mechanical dilatation is not adequate to activate 
nociceptors and cause migraine headache (163), and indeed, migraine can be 
induced, e.g. by sildenafil, without initial dilatation of the middle cerebral artery (164). 
 
While it may be reasonable at this point to discard vasodilation as a direct cause of 
migraine, more studies are needed before eliminating blood vessels from the list of 
factors contributing to the pathophysiology of migraine. Both normal and pathological 
events occurring within and between vascular cells could mediate bi-directional 
communication between vessels and the nervous system, without the need for 
changes in vascular tone (165). Blood vessels consist of a variety of cell types that 
both release and respond to numerous mediators including growth factors, cytokines, 
adenosine triphosphate (ATP), and nitric oxide (NO), many of which can sensitize 
trigeminal neurons. In addition, the majority of genomic loci identified in GWAS to be 
associated with migraine without aura are involved in pathways associated with 
vascular function (20, 23). Hence, it could still be possible that blood vessels play a 
role in migraine pathophysiology in the absence of vasodilation. 
 
The postdrome phase 
About 80% of migraine patients report at least one non-headache symptom following 
the end of their headache, while the disability scores remain high (68). The migraine 
postdrome is the least studied and least understood phase of migraine. Only recently, 
functional imaging showed widespread reduction in brain-blood flow in the postdrome, 
but at least some persistent blood flow increase in the occipital cortex (77, 166).  
 
The evolutive process of migraine chronification 
 
Chronic migraine (CM) is a disabling, underdiagnosed and undertreated disorder, 
affecting ~ 1-2% of the general population (167, 168). Progression from episodic to 
chronic migraine is a clinical reality (169, 170). Studies show that each year 2.5% of 
episodic migraine patients progress into chronic migraine (171) which appears as a 
distinct entity in the classification of the International Headache Society (chronic 
migraine >15 migraine days per month) (67). The nosology of CM has several clinical 
implications, including the elimination of modifiable risk factors and the therapeutic 
preventive options for CM patients.  
Patients with chronic migraine, have a significantly higher incidence of positive family 
history of migraine, menstrual aggravation of migraine, identifiable trigger factors, 
associated  symptoms, and early morning awakening with headache (172). A number 
of risk factors have been identified to double the risk for migraine chronification (173), 
including de novo iincreasedincreased migraine attack frequency and overuse of acute 
migraine medications (174-176), ineffective acute treatment that could lead to 
medication overuse (177), depression (178), which is a common comorbidity of 
migraine, and lifestyle factors such as stress, high caffeine intake and obesity (174, 
179).  
Certainly, either genetic factors or the presence of CM itself, induce functional and 
plastic changes in the brain of patients. In a recent resting-state fMRI study in chronic 
migraine patients without medication overuse it was shown that CM can progressively 
induce modifications in the CNS including large-scale reorganisation of functional 
cortical networks and interactive neuronal networks including the default mode 
network, the executive control network and the dorsal attention system (180). These 
are interesting outcomes as CM can impair the attention network resulting in 
impairment in executive functions (180).  Additionally, a number of brain imaging 
studies showed changes in gray matter volume, as well as in white matter 
hyperintensities in CM patients, compared to episodic patients (181-185). Whether 
such structural changes have Aany potential functional consequences of such 
structural changes remains unknow. 
The physiological mechanisms that underlie the development of chronic migraine from 
its episodic form are not understood. Cortical excitability appears to be abnormal in 
chronic migraine patients, but this could be a consequence of the disease and not a 
driver of the chronification (186, 187). Here we will discuss the role of inflammation 
and central sensitization in the evolutive process of chronic migraine. 
 
Inflammation and Ccentral sensitization in the pathophysiology of migraine 
chronification 
The question whether inflammation could contribute in the activation of the trigeminal 
system in a manner that could drive the migraine headache and be implicated in the 
evolutive process of migraine chronification remains relevant in migraine 
pathophysiology and treatment (188). Indeed, the broad use of non-steroidal anti-
inflammatory drugs for the acute treatment of headache supports the involvement of 
some neuroimmune responses in the development of migraine (189, 190), while 
steroid injections in the region of the greater occipital nerve, are widely used as a 
preventive method in chronic migraine (191, 192). 
In animals, sustained CGRP release may induce peripheral sensitization (193) likely 
due to release of inflammatory mediators (bradykinin, prostaglandins, etc.) from nerve 
endings and cells of immune system (194-196).  During a migraine attack that can last 
for up to 72 hours, the levels of the neuropeptide CGRP is increased (139). This leads 
to continuous activation of C-fibers because they store CGRP and of Aδ-fibers which 
contains CGRP receptors. This activation may lead to production and release of 
inflammatory cytokines, not only in the dura, but possibly also in neuronal cell bodies, 
which are localized in the TG. In addition, there are CGRP receptors on ganglion cells 
(197). Indeed, cytokines and chemokines may be released by neurons, microglia, 
astrocytes, macrophages and T cells, and activate pain neurons directly via activation 
of non-neuronal cells, depending on the expression of their receptors. 
Major cytokines have been implicated in the pathway resulting in neurogenic 
inflammation, including tumor necrosis factor (TNF)-α, IL-1β and IL-6 (198). TNF-α, a 
potential pain mediators in neurovascular inflammatory condition, has been suggested 
to be involved in the initiation and progression of a migraine attack (199). Studies have 
demonstrated changes in plasma, serum, or urine levels of TNF-α in migraine patients 
during attacks and attack free intervals (200, 201). Franceschini and coworkers 
reported that mRNA expression of TNF-α increased following migraine induction in 
animal models (202). Elevated TNF-α serum levels in humans, even in outside of 
attacks, confirm a possible role of TNF-α in migraine (203). A direct pathogenic role of 
TNF-α has not been reported during the use of this antibody in RA or MC/UC. 
Considering the very high prevalence of migraine, several hundred-thousand migraine 
patients must have received TNF-α antibody but there are no reports on any 
prevention of migraine attacks, not even in case-reports. This suggests that preventing 
TNF-α inflammation is not a viable anti-migraine target.  
Although strong and direct trigeminal stimulation causes release of CGRP and 
substance P which may lead to neurogenic inflammation in animal models (reviewed 
by (199), it appears to have minor impact in acute migraine. In the line of the 
hypothesis that continued stimulation of both C-fibers and Aδ-fibers can cause TG 
inflammation and hence be implicated in chronification, this has been studied to some 
extent experimentally; (i) In cultured trigeminal neurons, with focus on the 
inflammatory pathways (204, 205). (ii) Administered CFA (Complete Freunds’ 
Adjuvant) into the temporomandibular joint (TMJ), which elicited activation of 
trigeminal ganglion (TG) neurons (206). (iii) Trigeminal activation using chemical 
stimulation of the dura mater with CFA, to test whether application of CFA on the 
surface of the dura mater can cause long-term activation of the TG, serving as a model 
of migraine chronification (207) and activation of the trigeminal nucleus caudalis 
leading to central sensitization (208). 
The above experiments suggest that inflammation indeed could activate TG. Using 
culture of isolated trigeminal neurons as a model for studies of neurons and glial cells, 
reportedly there was enhanced expression of CGRP, and of the mitogen-activated 
protein (MAP) kinase both in neurons and in SGCs following inflammation. The 
activation of a MAP kinase–dependent inflammatory signal pathway is involved in 
over-expression of CGRP in nociceptive neurons and could participate in generating 
pain hypersensitivity (209). Looking further into in vivo inflammation, administration of 
CFA into the TMJ, elicits activation of TG by increased expression of pERK1/2, pp38, 
CaMKII, NF-κB and DREAM after 2 and 10 days. Local inflammation in the TMJ, 
induced by CFA, results in an upstream inflammation response in the TG where the 
TMJ sensory fibers have their cell bodies. Interestingly, this involves both neurons and 
SGCs which together represent one anatomical and functional unit (206).  
Local inflammation of dura mater can induce inflammatory activation in the TG. 
Application of inflammatory soup (IS) (210, 211), or CFA onto the dural surface 
induced changes in the expression of pERK1/2, IL-1β and CGRP positive nerve fibers 
in the TG illustrating that the application of inflammatory substances onto the dura 
mater could be used as an animal model for long term activation of the 
trigeminovascular system (207). Application of CFA also induced activation (increased 
expression of c-Fos) of the central part of the trigemino-vascular system: the TNC and 
C1-C2 regions of the spinal cord (208). Interestingly, the inflammation could be blocked 
by the administration of a kynurenic acid analogue (SZR72), precursor of a 
glutamatergic antagonist and an anti-inflammatory substance (208, 212). All the above 
evidence suggest that inflammation can be responsible for the development of at least 
peripheral sensitization that could then lead to the development of central 
sensitization. 
The concept of central sensitization is relevant not only for the development of chronic 
migraine, but also for the development of any chronic pain condition. Increased 
nociceptive processing, particularly due to the development of peripheral sensitization 
that could occur if indeed the trigeminal system is sustainably activated during 
migraine attacks, could lead to the development of central sensitization. Studies 
looking at biomarkers of functions of the trigeminal and autonomic systems identified 
important differences in the interictal state of chronic migraineurs compared to the 
interictal period of episodic migraineurs, suggesting a higher level of interictal activity 
of the trigeminal and cranial autonomic system in chronic migraineurs (173). In 
particular, interictal levels of CGRP and vasoactive intestinal peptide (VIP) are higher 
in chronic than in episodic migraine (213-215). Additionally, in animal models it has 
been demonstrated that chronic exposure to triptans could lead to the development of 
sensitization (216).  
Central sensitization refers to altered behavioural of second order neurons and even 
of third order thalamic neurons, and is characterized by increased excitability, increase 
synaptic strength and enlargement of their receptive fields (217-219). Clinically, central 
sensitization is manifested as a state of either hyperalgesia- an exaggerated pain in 
response to a stimulus that normally causes mild pain, or allodynia- a pain response 
to a normally non painful stimulus, and exaggerated pain response referred outside 
the original pain site (220). These persistent sensory responses to noxious stimuli 
and long-lasting synaptic plasticity at spinal and supraspinal levels could be providing 
the neuronal basis for persistent pain and “pain memory” in chronic migraine (221-223). 
Central sensitization is a glutamate-dependent process and at least, NMDA receptor 
activation seems to be pivotal for the induction of central sensitization in neuronal 
fibres innervating the dura matter  (224).  
Indeed, during a migraine headache about 80% of migraine patients develop 
cutaneous allodynia, characterised by increased skin sensitivity, mostly within the 
referred area of pain of the ipsilateral head (225, 226). Stimulation of nociceptive 
afferent of the dura mater leads to a sensitization of second-order neurons receiving 
cervical input (227). About two thirds of the patients developing cutaneous allodynia 
report that untreated migraine attacks will result in a spread of allodynia to the other 
side of the head or the forearm (225, 226), indicating the involvement of higher extra-
trigeminal processes. The limb or upper body allodynia seen in migraineurs, and the 
extend of cutaneous allodynia could be due to the development and spread of 
neuronal sensitization from second order neurons in the TCC, to third order neurons 
in the thalamus (220, 225). Hence, repeated attacks of peripheral and central 
sensitization could lead to the development of chronic migraine.  
Central sensitization is associated with abnormal neuronal hyperexcitability in the 
TCC, due to an increase of the sensory inputs arriving from nociceptors on peripheral 
trigeminal fibres that supply the affected area, which is a consequence of peripheral 
sensitization (211). Topical application of inflammatory agents on the rat dura, which 
induces long-lasting activation of the trigeminovascular pathway (210, 228, 229), 
provokes long lasting sensitization in trigeminocervical neurons that receive 
convergent inputs from the intracranial dura and extracranial periorbital skin. This 
neuronal sensitization is manifested as increased responsiveness to mechanical 
stimulation of the dura, to mechanical and thermal stimulation of the skin, and 
expansion of dura and cutaneous receptive fields (210). These changes are parallel 
to an increase of the extracellular glutamate concentration of second order neurons in 
the TCC (230), and suggest an important contribution of glutamate and its receptors 
in allodynia (230).  
Another factor that could contribute to the development of central sensitization and the 
susceptibility in developing chronic migraine could be a dysfunction in pain modulating 
systems. An imbalance of pain inhibition and facilitation could participate in the 
development or maintenance of sensitization and could contribute to the development 
of chronic migraine (231, 232). What is interesting though, is that in at least 60-70% 
of patients, CM can be blocked by treatments that act peripherally at least on trigeminal 
fibres, such as the newly developed mAbs against the CGRP system and botulinum 
toxin.  This further supports an important role of the trigeminal system as peripheral 
sensory inputs are important in sustaining central drive in CM.  
 
Does inflammation have a role in the pathophysiology of migraine chronification? 
The question whether inflammation could contribute in the activation of the trigeminal 
system in a manner that could drive the migraine headache and be implicated in the 
evolutive process of migraine chronification remains relevant in migraine 
pathophysiology and treatment (188). Indeed, the broad use of non-steroidal anti-
inflammatory drugs for the acute treatment of headache supports the involvement of 
some neuroimmune responses in the development of migraine (189, 190), while 
steroid injections in the region of the greater occipital nerve, are widely used as a 
preventive method in chronic migraine (191, 192). 
In animals, sustained CGRP release may induce peripheral sensitization (193) likely 
due to release of inflammatory mediators (bradykinin, prostaglandins, etc.) from nerve 
endings and cells of immune system (194-196).   
During a migraine attack that can last for up to 72 hours, the levels of the neuropeptide 
CGRP is increased (139). This leads to continuous activation of C-fibers because they 
store CGRP and of Aδ-fibers which contains CGRP receptors. This activation may 
lead to production and release of inflammatory cytokines, not only in the dura, but 
possibly also in neuronal cell bodies, which are localized in the TG. In addition, there 
are CGRP receptors on ganglion cells (197). Indeed, cytokines and chemokines may 
be released by neurons, microglia, astrocytes, macrophages and T cells, and activate 
pain neurons directly via activation of non-neuronal cells, depending on the expression 
of their receptors. 
Major cytokines have been implicated in the pathway resulting in neurogenic 
inflammation, including tumor necrosis factor (TNF)-α, IL-1β and IL-6 (198). TNF-α, a 
potential pain mediators in neurovascular inflammatory condition, has been suggested 
to be involved in the initiation and progression of a migraine attack (199). Studies have 
demonstrated changes in plasma, serum, or urine levels of TNF-α in migraine patients 
during attacks and attack free intervals (200, 201). Franceschini and coworkers 
reported that mRNA expression of TNF-α increased following migraine induction in 
animal models (202). Elevated TNF-α serum levels in humans, even in outside of 
attacks, confirm a possible role of TNF-α in migraine (203). A direct pathogenic role of 
TNF-α has not been reported during the use of this antibody in RA or MC/UC. 
Considering the very high prevalence of migraine, several hundred-thousand migraine 
patients must have received TNF-α antibody but there are no reports on any 
prevention of migraine attacks, not even in case-reports. This suggests that preventing 
TNF-α inflammation is not a viable anti-migraine target.  
Although strong and direct trigeminal stimulation causes release of CGRP and 
substance P which may lead to neurogenic inflammation in animal models (reviewed 
by (199), it appears to have minor impact in acute migraine. In the line of the 
hypothesis that continued stimulation of both C-fibers and Aδ-fibers can cause TG 
inflammation and hence be implicated in chronification, this has been studied to some 
extent experimentally; (i) In cultured trigeminal neurons, with focus on the 
inflammatory pathways (204, 205). (ii) Administered CFA (Complete Freunds’ 
Adjuvant) into the temporomandibular joint (TMJ), which elicited activation of 
trigeminal ganglion (TG) neurons (206). (iii) Trigeminal activation using chemical 
stimulation of the dura mater with CFA, to test whether application of CFA on the 
surface of the dura mater can cause long-term activation of the TG, serving as a model 
of migraine chronification (207) and activation of the trigeminal nucleus caudalis 
leading to central sensitization (208). 
The above experiments suggest that inflammation indeed could activate TG. Using 
culture of isolated trigeminal neurons as a model for studies of neurons and glial cells, 
reportedly there was enhanced expression of CGRP, and of the mitogen-activated 
protein (MAP) kinase both in neurons and in SGCs following inflammation. The 
activation of a MAP kinase–dependent inflammatory signal pathway is involved in 
over-expression of CGRP in nociceptive neurons and could participate in generating 
pain hypersensitivity (209). Looking further into in vivo inflammation, administration of 
CFA into the TMJ, elicits activation of TG by increased expression of pERK1/2, pp38, 
CaMKII, NF-κB and DREAM after 2 and 10 days. Local inflammation in the TMJ, 
induced by CFA, results in an upstream inflammation response in the TG where the 
TMJ sensory fibers have their cell bodies. Interestingly, this involves both neurons and 
SGCs which together represent one anatomical and functional unit (206).  
Application of inflammatory substances onto the dura mater or chemical stimulation of 
the dural receptive fields causes hypersensitivity to mechanical and thermal 
stimulation together with direct activation of the TG (210). Local inflammation of dura 
mater can induce inflammatory activation in the TG. Application of inflammatory soup 
(IS) (210, 211), or CFA onto the dural surface induced changes in the expression of 
pERK1/2, IL-1β and CGRP positive nerve fibers in the TG illustrating that the 
application of inflammatory substances onto the dura mater could be used as an 
animal model for long term activation of the trigeminovascular system (207). 
Application of CFA also induced activation (increased expression of c-Fos) of the 
central part of the trigemino-vascular system: the TNC and C1-C2 regions of the spinal 
cord (208). Interestingly, the inflammation could be blocked by the administration of a 
kynurenic acid analogue (SZR72), precursor of a glutamatergic antagonist and an anti-
inflammatory substance (208, 212).  
 
Conclusions: 
Migraine clinical and pathophysiological mechanisms are not static and evolve 
continuously. During lifespan the clinical phenotype of migraine changes. These 
changes may include transformation from episodic to chronic migraine or even a 
disappearance of some or all migraine symptoms all together.  Genetic and epigenetic 
susceptibility may be responsible for such changes, although to date, studies failed to 
shed any light on how such genetic alterations may be responsible for migraine 
pathophysiology or any evolutive mechanism. On the other hand, anatomical changes 
in the brain of a migraine patient exist even from early childhood, but they do not seem 
to have any functional consequences. The causality dilemma of whether such changes 
are responsible for how migraine evolves, or whether migraine mechanisms drive 
these anatomic changes, remains to be answered. Even in its episodic form, migraine 
is an evolutive condition with different mechanisms involved in the evolutive process 
of a migraine attack. These mechanisms include hypothalamic alterations during the 
premonitory phase, cortical excitability in the aura phase, activation of the ascending 
trigeminothalamic pain pathway with an involvement of the peripheral trigeminal arm 
during the headache phase, and potential cortical changes during the postdrome 
phase. How migraine headache is triggered following hypothalamic activation remains 
unknown. A potential involvement of the parasympathetic pathway is possible, as it 
could be influenced by hypothalamic changes and in turn activate the trigeminal 
system through the trigemino-autonomic arc. Such a mechanisms could explain 
activation of the peripheral trigeminal system from a brain-initiated event. The 
mechanisms that underlie the development of chronic migraine from its episodic form 
are not well understood. Several factors have been identified to increase the risk for 
migraine chronification. Inflammation and central sensitization play a significant role in 
the evolutive mechanisms of chronic migraine. 
The continuous changes in migraine phenotype and pathophysiology changes during 
a migraine attack, between episodic and chronic migraine and during the patient 
lifespan itself, making make migraine, even in its episodic form, a chronic evolutive 
disease.  
 
 
Figure Legend 1: 
Migraine is cyclic disorders with a complex sequence of symptoms within every 
headache attack. In its episodic form, migraine is characterised by recurrent attacks 
involving different phases, with a complex sequence of symptoms within every phase.  
Significant advances have been made in characterising migraine as a brain disorder 
and in identifying evolutive functional changes in different brain areas during the 
different phases of a migraine attack.  
 
 
Figure Legend 2: 
Migraine pathophysiology involves activation of the hypothalamic region during the 
early premonitory phase, and activation of the trigeminal system during the headache 
phase. Cortical spreading depression (CSD) is thought to be the biological process of 
the migraine aura. How activation of the hypothalamus may lead to the development 
of CSD and activation of the trigeminal system remains unknown. Potentially the 
hypothalamus may activate direct or indirect pathways involving other brain areas, 
such us the brainstem, or the parasympathetic system, leading to the development of 
migraine aura and activation of the ascending trigeminothalamic pathway.   
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